Message #2 From:
NewsBot Date: October 24, 2005 03:30:00 AM
EVSD News Endovasc to Attend BioNetwork 2005 Conference
MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 24, 2005--Endovasc, Inc. - (OTCBB: EVSC) (OTC:EVSD) a business development corporation that pioneers cardiovascular and metabolic drug therapies, announced today that the Company's President and CEO, Diane Dottavio, will be attending The BioNetwork 2005 Conference in Laguna Niguel, CA on October 24 - 26.
The BioNetwork 2005 is the 3rd annual pharmaceutical-biotech partnering conference with over 300 senior-level business development, alliance management and licensing decision-makers in attendance. BioNetwork paves the road for long-term, lucrative alliances in the Pharmaceutical-Biotechnology industry by providing one-to-one meeting rooms and an International Development Summit.
"I am very excited to attend the BioNetwork 2005 Conference this year. We believe that Liprostin can become the new standard of care for patients with Peripheral Vascular Disease and this event is a fantastic opportunity to network with our peers in both the biotech and pharmaceutical industry. The agenda and atmosphere of the conference is conducive to developing relationships that can mature into valuable partnerships in the future," commented Diane Dottavio, Endovasc President and CEO.
About Endovasc
Endovasc, Inc., established in 1996, is a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's subsidiaries include: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Nutraceutical Development Corporation which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product; and Prostent, a stent coating technology.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.
